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RESEARCH ARTICLE

Dysosteosclerosis: Clinical and Radiological Evolution
Reﬂecting Genetic Heterogeneity
Serap Turan,1 Steven Mumm,2,3 Ceren Alavanda,4 Betul Sare Kaygusuz,1 Busra Gurpinar Tosun,1
Ahmet Arman,4 Margaret Huskey,2 Tulay Guran,1 Shenghui Duan,2 Abdullah Bereket,1 and
Michael P. Whyte2,3
1

Pediatric Endocrinology and Diabetes, Marmara University School of Medicine, Başıbüyük Mah. Maltepe Başıbüyük Yolu Sok. No:9/2, Istanbul,
34854, Türkiye
2
Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA
3
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO, USA
4
Medical Genetics, Marmara University Faculty of Medicine, Istanbul, Turkey

ABSTRACT
Dysosteosclerosis (DSS), the term coined in 1968 for ultrarare dysplasia of the skeleton featuring platyspondyly with focal
appendicular osteosclerosis, has become generic by encompassing the genetic heterogeneity recently reported for this phenotype.
We studied four unrelated Turkish patients with DSS to advance understanding of the new nosology. Patient 1 suffered femur
fractures beginning at age 1 year. DSS was suspected from marked metaphyseal osteosclerosis in early childhood and subsequently
platyspondyly accompanying patchy osteosclerosis of her appendicular skeleton. She harbored in SLC29A3, in 2012 the ﬁrst gene
associated with DSS, a unique homozygous duplication (c.303_320dup, p.102_107dupYFESYL). Patient 2 presented similarly with
fractures and metaphyseal osteosclerosis but with no platyspondyly at age 2 months. She was homozygous for a novel nonsense
mutation in SLC29A3 (c.1284C>G, p.Tyr428*). Patient 3 had ocular disease at age 2 years, presented for short stature at age 11 years,
and did not begin to fracture until age 16 years. Radiographs showed mild platyspondyly and focal metaphyseal and femoral osteosclerosis. She was homozygous for a unique splice site mutation in TNFRSF11A (c.616+3A>G). Patient 4 at age 2 years manifested
developmental delay and frequent infections but did not fracture. He had unique metadiaphyseal splaying and osteosclerosis, vertebral end-plate osteosclerosis, and cortical thinning of long bones but no mutation was detected of SLC29A3, TNFRSF11A, TCIRG1,
LRRK1, or CSF1R associated with DSS. We ﬁnd that DSS from defective SLC29A3 presents earliest and with fractures. DSS from compromised TNFRSF11A can lead to optic atrophy as an early ﬁnding. Negative mutation analysis in patient 4 suggests further genetic
heterogeneity underlying the skeletal phenotype of DSS. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf
of American Society for Bone and Mineral Research.
KEY WORDS: BONE TURNOVER; COLONY STIMULATING FACTOR; METAPHYSEAL SCLEROSIS; OSTEOCALCIN; OSTEOPETROSIS; OSTEOSCLEROSIS; PYLE

DISEASE; SKELETAL DYSPLASIA; SLC29A3; TCIRG1; TNFRSF11A; CSF1R; FRACTURES; RANK; RANKL; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR ΚB; DEVELOPMENTAL DELAY; DUAL-ENERGY X-RAY ABSORPTIOMETRY; HYPERCALCEMIA; LRRK1; METABOLIC BONE DISEASE; METAPHYSEAL DYSPLASIA

Introduction

D

ysosteosclerosis (DSS or DOS), considered an osteopetrosis
(OPT) when ﬁrst described in 1934 by Ellis,(1) was named in
1968 by Spranger and colleagues(2) to emphasize its patchy
osteosclerosis(1,2) accompanied by platyspondyly with vertebral
endplate thickening (OMIM % 224300).(3) During infancy and
early childhood the osteosclerosis of DSS is widely distributed

but especially pronounced in expanded metaphyses, whereas
diaphyses are broad and radiodense or radiolucent.(2–10) Then,
these features of DSS evolve.(4–6,10) Expanded osteosclerotic
metaphyses become osteopenic, sometimes including portions
of the diaphyses where the cortex may be thin.(4,6,10) Cranial
nerve palsies and developmental delay can occur.(6–10) Skin
changes are sometimes noted.(1,4,7) By middle age, there can
be diffuse osteosclerosis of cranial bones, mandible, maxilla,
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mastoid, and skull base.(6,10,11) Diagnosing DSS may be delayed
because its radiographic hallmarks can go undocumented or misunderstood. In 2010, we reported that DSS in early childhoodrepresents an “osteoclast-poor” form of OPT(4) wherein some
heritable defect transiently abrogates osteoclastogenesis.(4,5)
Delineation of the etiology of DSS began in 2012 when we
reported two girls who harbored biallelic mutations of the nucleoside transporter gene “solute carrier family 29 member 3”
(SLC29A3).(5) The following year, Sule and colleagues(12) found
no SLC29A3 defect in one patient,(6,10) thereby suggesting
genetic heterogeneity for DSS. In 2016, Iida and colleagues(13)
associated “leucine rich repeat kinase 1” (LRRK1) with osteosclerotic metaphyseal dysplasia (OMD; OMIM % 615198)(3) featuring characteristics of DSS.(3,13–17) In 2018, two genes
underlying autosomal recessive OPT(18,19) became associated
with DSS(20,21): (i) “tumor necrosis factor receptor superfamily
member 11A” (TNFRSF11A) that encodes receptor activator of
NF-κB (RANK) (OMIM # 612301),(3) and (ii) “T-cell immune regulator 1” (TCIRG1) that encodes a component of the vacuolar proton
(H+) pump necessary for osteoclasts (OCs) to produce hydrochloric acid (OMIM # 259700).(3) Most recently, in 2019, biallelic
mutations of “colony-stimulating factor 1 receptor” (CSF1R)(22)
were associated with dysosteosclerosis-Pyle disease (DSS-PD),
also called “brain abnormalities, neurodegeneration, and dysosteosclerosis” (BANDDOS: OMIM # 618476).(3)
Herein, we characterize the phenotype of four young unrelated Turkish patients with DSS. Two carried novel homozygous
SLC29A3 defects, one a novel homozygous TNFRSF11A change,
and one for whom no mutation was found.

Patients and Methods
Patients
The principal clinical and radiological features and results from
mutation analyses of our four patients are detailed below and
summarized in Table 1.
Patient 1
Patient 1, 23 years-of-age, was homozygous for a novel defect in
SLC29A3. In 2015, we brieﬂy reported her features of DSS and
unique mutation.(23) Her parents were ﬁrst-degree cousins. At
age 4 months, severe anemia (hemoglobin [Hb] 3 mg/dL) was
attributed to OPT despite no hemolysis or extramedullary hematopoiesis. Subsequently, folic acid supplementation (serum
folate 2.9 ng/mL, normal [Nl] 2.0–9.0) corrected this problem.
Fracturing began at about age 1 year. Shedding of her deciduous teeth was delayed. Neurodevelopmental milestones were
normal with good grades at school. Four of at least seven femoral
breaks required surgery, including one to remove metal plates. A
supracondylar specimen of femur reportedly showed focal, irregular, lytic, and dysplastic enchondral bone adjacent to mature
compact bone. Skeletal scintigraphy at age 12 years revealed
symmetrically increased radionuclide uptake attributed to
increased osteoblastic activity at the proximal and distal femurs
and at the proximal humeral and tibial metadiaphyses. Sequential dual-energy X-ray absorptiometry (DXA) demonstrated
(Lunar Prodigy; GE Healthcare, Piscataway, NJ, USA) markedly
elevated but decreasing areal bone mineral density (aBMD) at
the L1–L4 spine; +10.8 at age 7 years, +6.3 at age
10 years, +6.4 at age 15 years, +8.7 at age 17 years, +7 at age
22 years, and +5.6 at age 23 years. Bone turnover markers
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(BTMs) spanning ages 11 to 23 years included elevated urinary
deoxypyridinoline (DPD; Immulite® 2000, Siemens Healthcare
Diagnostic Products Ltd., Llanberis, Gwynedd, UK), but normal
serum alkaline phosphatase (ALP; Hitachi 917; Roche Diagnostics
International Ltd., Mannheim, Germany), C-terminal telopeptide
(CTX; Cobas e411; Roche Diagnostics International Ltd., Rotkreuz,
Switzerland), and procollagen type 1 N-terminal propeptide (P1NP)
(Cobas e411; Roche Diagnostics International Ltd., Rotkreuz,
Switzerland). Serum osteocalcin (OCN) levels (Immulite® 2000,
Siemens Healthcare Diagnostic Products Ltd., Llanberis, Gwynedd, UK) ranged from low to high (Table 2).
Referral at age 17 years was for recurring fractures. Her height
was 146 cm ( 2.8 standard deviation [SD]), arm span 159 cm;
and arm span-height difference 12.7 cm (Nl 6.3 to +6.5). She
weighed 53 kg ( 0.7 SD). Mid-parenteral height was 156 cm,
and her healthy 30-year-old and 28-year-old sisters were
158 cm and 161 cm tall, respectively. Disproportionate short
stature included a short trunk, but prior femoral fractures
explained her nearly normal upper-lower segment ratio of 0.8
(Nl 0.88–1.1). Mild prognathism, prominent nose, short philtrum,
small maxillary lateral incisors, and broad shoulders were apparent. At age 18 years, hypertrichosis/hirsutism (Ferriman-Gallwey
score = 15) was without hyperandrogenemia or menstrual irregularity. Audiology and fundus and visual ﬁeld examinations were
normal. DSS became suspected when her radiographs revealed
marked metaphyseal sclerosis that became increasingly generalized from age 1–15 years (Fig. 1A-D). Patchy diaphyseal osteosclerosis, platyspondyly with “sandwich vertebrae,” and
thickening and osteosclerosis of her calvarium were striking
(Fig. 1F-H). Then, accompanying the decline in spinal aBMD, long
bone osteosclerosis diminished, leaving scarce and lacy sclerotic
areas within an osteopenic background. At age 23 years, her
long bones were under-modeled and osteopenic, whereas fractures had healed with osteosclerosis (Fig. 1E).
Patient 2
Patient 2 was homozygous for a different novel SLC29A3 mutation. Her parents were second-degree cousins. Fetal ultrasound
indicated no antenatal fractures or deformities. Pregnancy and
delivery were uneventful and birth weight was 3270 g. At age
2 months, a ﬁbular fracture prompted referral for “osteogenesis
imperfecta.” Height, weight, and head circumference were
57.5 cm ( 0.22 SD), 4.7 kg ( 0.97 SD), and 38.5 cm ( 0.64 SD),
respectively. Frontal bossing, open anterior (3  4 cm) and posterior (0.5  0.5 cm) fontanelles, gray-blue sclera, mild hypertrichosis, and restricted elbow extension were present. Growth
was good with appropriate neurodevelopmental milestones at
age 6 months. Audiology, ophthalmology, metabolic and heavy
metal screening, and BTMs were normal except for elevated urinary DPD (Table 2). Metaphyseal osteosclerosis was not apparent
at age 19 days, but at age 2 months was documented in her
femurs, proximal humeri, and metacarpals when referred to our
clinic. At age 6 months, platyspondyly and “sandwich vertebrae”
were absent on spinal radiographs (Fig. 2A-F).
Patient 3
Patient 3, 21 years old, harbored a unique homozygous mutation
in TNFRSF11A. Her parents were consanguineous. At age 2 years,
nystagmus, pale optic disks, and increased retinal vessel tortuosity were noted. She presented to us at age 10 years with short
stature; height 121 cm ( 3.3 SD) and weight 23.6 kg ( 2.2 SD).
Body proportions were normal (upper-lower segment ratio 1.04
JBMR Plus (WOA)

Table 1. Genetic, Clinical, and Radiographic Findings of Our Four Patients
Subject
Genetic defect
Parental consanguinity
Sex
Age at presentation
Complication
Age last visit
Birth weight (gestational
age)
Height (SD)
Target height (SD)
Age of ﬁrst fracture (# of
fractures)
Skin changes
Optic atrophy
Developmental delay
Recurrent infections
Dental problems
Radiographs
Platyspondyly
Erlenmeyer ﬂask
deformity
Diaphyseal osteopenia
and thin cortices
Osteosclerosis
Vertebral
Rib
Pelvic bone
Calvariae
Metaphyseal
Diaphyseal
Diaphyseal focal
sclerosis (femur)
Changing with age
Hand and forearm
bones

Patient 1

Patient 2

Patient 3

SLC29A3 (c.303_320dup)
+
Female
4 months
Anemia
23 years
4 kg (term)

SLC29A3 (c.1284C>G)
+
Female
2 months
Fracture
6 months
3270 g (term)

TNFRSF11A (c.616+3A>G)
+
Female
10.6 years
Short stature
21 years
3010 g (term)

Male
27 months
Hypercalcemia
4.5 years
2200 g (36 weeks)

146.3 cm ( 2.8 SD)b
(ﬁnal)
156 cm ( 1.21)
12 months (>7)

62.5 cm ( 1.1)

138 cm ( 4.2 SD)b (ﬁnal)

90 cm ( 3.8)

158 cm ( 0.87)
2 months (1)

154 cm ( 1.55)
17 years (4)

173 cm ( 0.52)
–

Hypertrichosis

Hypertrichosis

None
+

Eczema

Delayed shedding of
deciduous teeth

Frequent carries

+
+

+

+

+

+

Mild
+

+
+
+
+

+
+
+

NA

+

a

+
Mild
+
+
+
+

None identiﬁed

Severe
+
Discoloration

+
+
+

Patient 4

+

a

+

Few and far between
+
+
+

+

+
+

Abbreviation: NA, not applicable.
a
Radiographs taken in older ages, osteosclerosis earlier not excluded.
b
Short trunk dwarﬁsm.

[Nl 0.86–1.08], and arm span/height difference 3.4 cm [Nl 7.8
to +6.1]). Family members were not short, and reportedly without heritable diseases. Pycnodysostosis was suspected because
her facial dysmorphism included proptosis, beaked nose, malar
hypoplasia, and short philtrum. Nystagmus had been ﬁrst
noticed at age 2 months, and was present at age 18 years when
cranial and orbital tomography showed bilateral proptosis and
thickening of optic nerve sheet indicating optic canal narrowing.
Poor oral hygiene, crowded teeth, and multiple caries were present. Immunoglobulin levels were not measured because there
had been no recurrent infections. Femoral fractures, three requiring surgery, began at age 16 years. Adult height was 138 cm
( 4.2 SD) with mid-parenteral height 154 cm ( 1.55 SD). Arm
span was 151 cm, arm span/height difference 12.2 cm (Nl 6.3
to +6.5 cm), and upper-lower segment ratio 0.88 (Nl 0.88–1.1)
showing that her short stature principally reﬂected her short
trunk. Cranial bones and ribs were osteosclerotic (Fig. 3A,C1).
JBMR® Plus

Platyspondyly with vertebral endplate osteosclerosis was present (Fig. 3,C2). Long bones featured osteopenia, thin cortices,
and wide metaphyses (Fig. 3E-F). Pycnodysostosis seemed
unlikely because hand radiographs lacked osteosclerosis or
acroosteolysis, and her osteopenic long bones featured localized
osteosclerosis consistent with DSS (Fig. 3B,E). DXA of L1–L4
revealed elevated aBMD and Z-scores increasing with age; +8.1 at
18 years, +9.3 at 19 years, and +10.7 at 21 years. BTMs spanning
17 to 21 years old were normal (Table 2). In 2017, we identiﬁed
her homozygous TNFRSF11A mutation in our research laboratory
(see Mutation analyses). Then, in 2018, Guo and colleagues(20)
reported her the ﬁrst example of DSS from TNFRSF11A mutation.
Patient 4
Patient 4, 11 years old, revealed in our research laboratory no
mutation in any of the ﬁve genes (SLC29A3, TNFRSF11A, LRRK1,
DYSOSTEOSCLEROSIS HETEROGENEITY
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Y(4)/N(0)
Mild Y(2)/Y(2)
Y(4)/N(0)
Y(4)/N(0)
Y(2)/Diffuse Y(2)/N(0)

Mild Y(6)/N(0)

Y(6)/N(0)
Y(5)/N(0)/ND(1)
Y(6)/N(0)

Y(3)/N(0)/ND(3)

Y(0)/N(0)/ND(2)

Y(2)/N(0)
Y(2)/N(0)
Y(2)/N(0)

Y(2)/N(0)

Y(2)/N(0)
Y(0)/N (2)
Y(0)/N(2)
Y(1)/N(1?)
Y(0)/N(2)
Y(0)/N(2)
Y(0)/N(2)
Y(0)/N(2)
Y(0)/N(2)
Y(1) Clavicle/N(1)
Y(0)/ND(1)/NA(1)

Y(3)/N(1)
Y(0)/N(2)/ND(2)
Y(3)/N(1)
Y(1)/N(2)/ND(1)
Yb(2)/N(1)/ND(1)
Y(1)/N(2)/ND(1)
Y(1)/N(3)
Y(0)/N(2)/ND(2)
Y(3)/N(0)/ND(1)
Y(3)/N(1)
Y(0)/N(0)/ND(2)/NA(2)

F(1)/M(1)
Indian(2)

15y, 10y

Age (years [y] or months
[m])
Short stature
Skin changes
Optic atrophy
Developmental delay
Recurrent infections
Anemia/pancytopenia
Hepatosplenomegaly
Hypercalcemia
Dental problems
Long bone fractures
Delayed fracture healing
Radiographs
Osteosclerosis of
calvaria
Platyspondyly
Vertebral sclerosis
Rib sclerosis/
thickening
Pelvis-peripheral
sclerosis

F(3)/M(1)
Turkish(2), Japanese(1)
British (1)

c.117+4A>C/
p.A796fs*34

TCIRG1 (2/1)(21)

16y, 59y, 2.3y, 5.3y

F(6)/M(0)
Turkish(4), ND(1),
Cameroonian (1)

Sex ratio
Ethnicity (families)

a

c.616+3A>G (Hom)
c.784G>T (Hom)
a
c.414_427+7del/c.1664del
p.R129C (Hom)

a

TNFRSF11A (4/4)(11,20,33,34)

2y, 5y, 5.6y, 22y, 11.1y,
5.5y
Y(5)/N(0)/ND(1)
Y(2)/N(4)
Y(0)/N(4)/ND(2)
Y(1)/N(5)
Y(3)/N(2)/ND(1)
Y(1)/N(3)/ND(2)
Y(0)/N(2)/ND(4)
Y(1)/N(3)/ND(2)
Y(2)/N(4)
Y(5)/N(1)
Y(1)/N(0)/ND(5)

c.303_320dup (Hom)
p.S203P/p.R386Q
p.R386Q(Hom)
p.P391H (Hom)
p.T449R (Hom)

SLC29A3 (6/6)(5,21,31,32)

Mutations

Genetic defect (#patient/
#family)

Table 2. Genetic, Clinical, and Radiological Spectrum of DSS

Diffuse Y(5)/N(2)/ND(1)

Y(7)/N(0)/ND(1)
Y(4)/N(2)/ND(2)
Y(3)/N(1?)/ND(4)

Y(7)/N(0)/ND(1)

F(7)/M(4)
Brazilian(1), Japanese(1),
Chaldean(2+3), Turkish (3),
American (1)
5y, 35y, 14y, 23y, 9y, 7y, 16y,
14y
Y(2)/N(5)/ND(1)
Y(0)/N(0)/ND(8)
Y(2)/N(3)/ND(3)
Y(8)/N(0)
Y(0)/N(0)/ND(8)
Y(0)/N(5)/ND(3)
Y(0)/N(7)/ND (1)
Y(0)/N(5)/ND(3)
Y(0)/N(0)/ND(8)
Y(2)/N(6)-Coccyx
Y(0)/N(0)/NA(6)/ND(2)

p.P132L/p.Q481*
p.S620delins40/p.K27del
p.P658Sfs*24 (Hom)
c.2763+1G>T (Hom)
p.Q481* (Het)

CSF1R (11/5)(22,35,36)

(Continues)

Y(4)/N(0)/ND(4)

Y(1)/N(4)/ND(3)
Y(6)/N(0)/ND(2)
Y(4)/N(0)/ND(4)

Mild Y(2)/N(1)/ND(5)

p.A34Pfs*33 (Hom)
p.E929* (Hom)
p.E1980Afs*66 (Hom)
p.A1991fs*31 (Hom)
p.T1989G1990del
(Hom)
F(4)/M(4)
Iranian(1), Indian(2),
Moroccan(1), Bulgarian
(1), Palestinian(3)
14m, 14y, 14y, 23y, 25y,
13.5y, 11.5y, 9m
Y(4)/N(3)/ND(1)
Y(0)/N(0)/ND(8)
Y(2)/N(3)/ND(3)
Y(2)/N(6)
Y b(2)/N(4)/ND(2)
Y(1)/N(2)/ND(5)
Y(1)/N(4)/ND(3)
Y(0)/N(3)/ND(5)
Y(5)/N(1)/ND(2)
Y(6)/N(2)
Y(0)/N(0)/ND(6)/NA(2)

LRRK1 (8/5)(13–17)

JBMR® Plus
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n

Y(2)/N(2)
Y(2)/N(2)
Y(0)/N(0)/ND(4)
Y(2)/N(2)

Y(0)/N(5)/ND(1)

Y(3)/N(2)/ND(1)

Y(3)/N(0)/ND(3)

Y(0)/N(4)/ND(2)

Craniosynostosis, intracranial
extramedullary
hematopoiesis

Y(2)/N(2)

Y(1)/N(5)

[+8.1 (2y), +11.9 (5y)]
[+8 (20 m), +7.1
(3.4y), +6.4 (4.5y), +5.1
(5.5y)]
[+0.6 (5.5y?)]
Delayed closure of
fontanelle (2),
Macrocephaly (1),
Melanocytic nevi

Y(1)/N(3)
Y(3)/N(0)/ND(1)

TNFRSF11A (4/4)(11,20,33,34)

Y(5)/N(0)/ND(1)
Y(4)/N(2)

SLC29A3 (6/6)(5,21,31,32)

N = no; NA = not applicable; ND = not deﬁned; Y = yes.
a
Splice donor site mutations.
b
Osteomyelitis.

Others

Metaphyseal sclerosis
Erlenmeyer ﬂask
deformity/
undertubulation
Diaphyseal osteopenia
and thin cortices
Diaphyseal diffuse
sclerosis
Diaphyseal focal
sclerosis
Changing sclerosis
with age
Normal bones of hand
and forearm bones
BMD Z-score (lumbar
DXA)

Genetic defect (#patient/
#family)

Table 2. Continued

Y(0)/N(2)

Y(0)/N(0)/ND(2)

Y(0)/N(2)

Y(2)/N(0)

Y(0)/N(2)

Y(2)/N(0)
Y(2)/N(0)

TCIRG1 (2/1)(21)

Brain malformations,
calcifying
leukoencephalopathy,
epilepsy

Y(0)/N(5)/ND(3)

Y(0)/N(0)/ND(8)

Y(8)/N(0)

Y(0)/N(8)

Y(8)/N(0)

Y(1)/N(6)/ND(1)
Y(8)/N(0)

CSF1R (11/5)(22,35,36)

Acroosteolysis,
osteonecrosis/
osteomyelitis of jaw

Y(0)/N(5)/ND(3)

Y(2)/N(0)/ND(6)

Y(6)/N(1)/ND(2)

Y(0)/N(8)

Y(3)/N(0)/ND(5)

Y(5)/N(3)
Mild Y(6)/N(0)/ND(2)

LRRK1 (8/5)(13–17)

Fig. 1. Patient 1. Evolution of radiographic ﬁndings at increasing age. (A) In early childhood the pelvis and metaphyses and epiphyses of the lower
extremities are densely osteosclerotic. (B) At age 6 years, osteosclerosis is more diffuse and also apparent in the lower spine. Right femoral tubulation error
and transverse healing fracture are apparent distally. (C) At age 13 years, the right femur shows coxa vara, diffuse but patchy osteosclerosis, loss of cortical
and medullary distinction, plate and screw ﬁxation of a proximal fracture, removal of distal femoral hardware, and metaphyseal and distal diaphyseal
expansion. The right knee is shown as an inset (arrow). (D) At age 15 years, the pelvis and femoral heads are densely osteosclerotic, but less so centrally,
giving a “bone-in-bone” appearance. At age 17 years, the femora are becoming osteopenic but with coarse trabeculation and focal osteosclerosis, have
hardware ﬁxation of a fracture, an unbridged distal right fracture (arrow) that persisted at age 18 years (not shown), and distal metadiaphyseal expansion.
(E) At age 23 years, standing radiograph shows improvements including the pelvis and lower extremities with decreased osteosclerosis and tubulation
error, improved mineralization, and a solidly bridged fracture (arrow). There is expanded metadiaphyseal bone in the distal femurs and tibias, overall
osteopenia, focal osteosclerosis, thick trabeculae, and bowing. (F) Anteroposterior and lateral views of the skull at age 12 years reveal mild diploic thickening and diffuse osteosclerosis that includes the base, orbits, facial bones, and cervical spine. (G.1) At age 17 years, the distal forearms have metadiaphyseal expansion and focal osteosclerosis. The carpals show peripheral osteosclerotic ringing, metacarpals and phalanges patchy osteosclerosis, and
metacarpals some error of tubulation. (G.2) At age 23 years; the tubulation errors are more prominent, but with improvement in the patchy osteosclerosis.
(H.1) Between ages 17-1/2 years and 22 years (H.2), the vertebral endplate sclerosis (“sandwich vertebrae”) is less, matching the BMD Z-scores that
decreased from +8.7 to +7. The vertebral body ﬂattening and decreasing osteosclerosis apparent in the later views of the pelvis were little changed
(not shown).

TCIRG1, and CSF1R) that had come to be associated with DSS (see
Discussion). His parents were unrelated. He weighed 2.2 kg
when delivered at 36 weeks gestation to a 25-year-old woman
who had noticed diminished fetal movement during the last
week of her pregnancy. Intensive care for 10 days included respiratory support for 3 days. At age 6 months, slow motor development was reported. At age 14 months, inborn-error-ofmetabolism studies were negative, and OMD was considered
when radiographs showed metaphyseal osteosclerosis. Remarkably, at age 27 months, fever, cough, and vomiting accompanied
unexplained severe hypercalcemia (19.8 mg/dL [Nl 8.8–10.6])
with physiologically suppressed serum parathyroid hormone
(PTH), hypophosphatemia, low-normal ALP, and normal
25-hydroxyvitamin D (Table 2). Intravenous hydration and pamidronate (1 mg/kg/day for 3 days) corrected the hypercalcemia,
which did not recur. Frequent respiratory tract infections required
four hospitalizations for pneumonia. Early developmental milestones were slightly delayed, but by age 2 years global motor
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retardation was apparent, and by age 4.5 years he could not sit,
walk, or pronounce words. Cranial magnetic resonance imaging
(MRI) was reportedly normal except for mild cortical atrophy.
When referred to us at age 28 months, his height, weight, and
head circumference Z-scores were 1.8, 4.2, and 3.0, respectively. Dysmorphic facial features included a wide forehead, triangular face with open mouth, high-arched palate, yellow
teeth, short nose with prominent nasal tip, long philtrum, mild
hypoplasia of alae nasi, nasal obstruction, rigid pinnae, almondshaped eyes with gray sclera, and laterally anteverted palpebral
ﬁssures (Kabuki makeup syndrome–like). Skeletal deformity
was absent, but spasticity and atrophic muscles were present.
Skin changes of DSS, such as red rashes, were present. Oral candidiasis was detected although serum immunoglobulin levels,
immune phenotyping, nitroblue tetrazolium (NBT) testing, metabolic screening (including phosphoethanolamine for hypophosphatasia), blood gases, and lead level were normal.
Adenoidectomy was performed at age 3.5 years. Scoliosis
JBMR Plus (WOA)

Fig. 2. Patient 2. Radiographic ﬁndings during infancy. (A) At age 19 days, anteroposterior radiograph of the chest shows minimal osteosclerosis. (B) At
age 2 months, marked metaphyseal osteosclerosis affects the proximal humeri (arrows). The clavicles, ribs, scapulae, and spine are osteosclerotic. (C) At
age 2 months, metaphyseal osteosclerosis had faded in the distal left radius and ulna, possibly due to healing fractures there, but is apparent in four metacarpals (arrows) and proximal ulna (arrow). (D) At age 2 months, the dense metaphyseal osteosclerosis is no longer prominent at the provisional zone of
calciﬁcation in the distal femur, and dense metaphyseal osteosclerosis is absent at the ends of the tibia (arrows). The proximal tibia and ﬁbula (arrow) show
healing fractures. Osteosclerosis is peripheral in the iliac bone and focal in the ischium and pubis. (E,F) At age 6 months, anteroposterior and lateral views
of the spine demonstrate thick and osteosclerotic ribs and osteosclerosis of the clavicles, scapulae, proximal humeri, spine (especially the cervical region),
and pelvis.

persisted from age 4.5 years. BTMs were unremarkable except
for low OCN, but assayed after pamidronate treatment
(Table 2). At age 11 years, hospitalizations for recurrent infections had ceased. He had not fractured. Radiographs revealed
wide sclerotic metaphyses with osteopenic diaphyses, wide sclerotic ribs, and “sandwich vertebrae” but without platyspondyly
(Fig. 4B-E). Osteosclerotic areas had receded since early childhood, but with increasingly osteopenic widened bones with thin
cortices (Fig. 4C1-E1 to C2-E2). His spinal aBMD was unchanged
from 0.54 to 0.52 g/cm2, therefore generating Z-scores that
decreased from +3.02 to +0.43 as he grew and aged.

Mutation analyses
Mutation analyses were performed for patients 1, 3, and 4 in our
research laboratory at Washington University School of Medicine, St. Louis, MO, USA. Written consent was obtained as
approved by the Marmara University Medical Faculty Research
Ethics Committee (MAR-Y-09.2021-623) Istanbul, Turkey in accordance with the 1964 Helsinki declaration and its later amendments. Coding exons and exon-intron boundaries of SLC29A3
were Sanger sequenced using methods we had developed.(4,5)
When no SLC29A3 mutation was identiﬁed (patients 3 and 4),
Ion Torrent (Thermo Fisher Scientiﬁc) next-generation sequencing (NGS) examined 35 genes that: (i) cause osteosclerotic disorders, (ii) condition skeletal remodeling, or (iii) reﬂect mouse
models featuring elevated bone mass: ie, TNFRSF11A (RANK),
TNFRSF11B (OPG), TNFSF11 (RANKL), VCP, SQSTM1, TGFB1, IFITM5,
MAFB, CSF1, CSF1R, TRAF6, RELA, RELB, REL, NFKB1, NFKB2, TFEB,
CA2, CLCN7, CTSK (CATHEPSIN K), OSTM1, PLEKHM1, TCIRG1, SOST,
JBMR® Plus

SLC29A3, LRP4, LRP5, LRP6, SNX10, FAM20C, FAM123B (AMER1),
TYROBP, LEMD3, DLX3, and PTDSS1.(4,5) Variants were then veriﬁed by Sanger sequencing. For patient 4, LRRK1 was Sanger
sequenced using primers we designed (sequences available on
request). At least 10 bases of intronic DNA sequence at each
exon/intron boundary were sequenced to identify potential
messenger RNA (mRNA) splice site mutations. Patient 2 was studied at Marmara University School of Medicine where clinical
exome sequencing was performed using SOPHIA Clinical Exome
Solution V2 via Illumina Nextseq 550 platform (Illumina, San
Diego, CA, USA). Twenty-seven genes: TNFRSF11A (RANK),
TNFRSF11B (OPG), VCP, SQSTM1, TGFB1, IFITM5, MAFB, CSF1,
CSF1R, TRAF6, NFKB2, CA2, CLCN7, CTSK (CATHEPSIN K), OSTM1,
TCIRG1, SOST, SLC29A3, LRP4, LRP5, LRP6, SNX10, FAM20C,
FAM123B (AMER1), TYROBP, LEMD3, and DLX3 were ﬁltered.
SOPHIA DDM-V4 analyzed the data. For segregation analysis,
we used the Illumina MiSeq platform.

Results
Mutational analyses
Patient 1
Sanger sequencing of SLC29A3 revealed a novel homozygous
18-basepair (bp) duplication in exon 3 (c.303_320dup,
p.102_107dupYFESYL) predicting in-frame tandem duplication of six amino acid residues (Fig. S1). Her consanguineous
parents and one of two healthy sisters were heterozygous
for this mutation.
DYSOSTEOSCLEROSIS HETEROGENEITY
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Fig. 3. Patient 3. Radiographic ﬁndings at age 17 years. (A.1,A.2) Anteroposterior and lateral views of the skull show thick diploic space and diffuse osteosclerosis including the base, orbits with sphenoid wings, petrous bones, maxilla, mandible, and cervical spine. (B.1,B.2) Bones of the right hand and forearm
are mildly undertubulated, but not osteosclerotic. (C.1,C.2) Osteosclerosis is marked in the wide ribs and present in portions of the clavicles. The vertebrae
are sclerotic and ﬂattened with coarse trabeculae and concavities of their superior and inferior margins are associated with disk expansion. Marked medullary cavity expansion distorts the proximal humeri showing cortical thinning and small focal metaphyseal osteosclerosis (arrows). (D) Anteroposterior
view of the pelvis and proximal femurs shows diffuse patchy osteosclerosis and sclerotic rings paralleling the iliac crests, asymmetry, osteosclerotic femoral heads, wide femoral necks and trochanteric regions, and coxa valga. On the right, there is osteosclerosis and obliteration of the medullary cavity
below the trochanters, a lateral cortical fracture line and intramedullary nail, and mild acetabular protrusio. On the left, a proximal femoral transverse fracture with plate-and-screw ﬁxation lacks solid bridging, although new bone is medial to the fracture. (E.1,E.2) The right femur and tibia/ﬁbula show marked
expansion of the medullary cavities. The femur and tibia demonstrated cortical thinning at their ends and mid-portion narrowing. The narrow mid femur
has no medullary cavity. Bone atrophy has occurred proximal to the superior end of the femoral nail. A healing mid-shaft ﬁbular fracture is apparent. (F)
The left femur shows marked medullary expansion and cortical thinning, focal areas of osteosclerosis, and an acute transverse fracture through its narrow
mid portion (F.1), ﬁxed internally with plate and screws (F.2). Computed tomography demonstrates the markedly thin cortex, expanded medullary cavity,
and thin trabeculae (F.3).

Patient 2
NGS of SLC29A3 revealed a novel homozygous nonsense mutation (c.1284C>G, p.Tyr428*) that was heterozygous in her consanguineous parents (Fig. S2).
Patient 3
All exons and adjacent mRNA splice sites of SLC29A3 were intact.
In 2017, our NGS revealed a novel homozygous splice donor site
variant (c.616+3A>G) in intron 6 of TNFRSF11A (Fig. S3). This variant was heterozygous in her mother; the father was not available for study. The following year, Guo and colleagues(20)
conﬁrmed this mutation and proposed it caused DSS (see
Discussion).

colleagues(22) in 2019 had reported deep intronic mutations in
CSF1R causing DSS, resulting in “abnormal inclusion of intron
sequences in the mRNA.” Additional methodologies to identify
this type of mutation (eg, reverse transcription-polymerase chain
reaction using patient-derived RNA) could not be undertaken for
this patient.

DSS phenotype of our patients
Our four patients’ clinical, radiographic, and genetic ﬁndings
indicating DSS (Table 1) and assessments of mineral and skeletal
metabolism (Table S1) were then compared with published
reports of DSS.

Patient 4
Our mutation analysis was negative for SLC29A3, TNFRSF11A,
TCIRG1, LRRK1, and CSF1R and the OPT-associated genes CLCN7,
TNFSF11, CA2, OSTM1, PLEKHM1, and SNX10. This included
sequencing all coding exons and at least 10 bases of intronic
DNA at exon/intron junctions while recognizing that Guo and
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Literature evaluation
The genotype/phenotype spectrum of DSS was assessed from
the literature using Medline, Embase, Scobus, Web of Science,
bone abstracts and Mendeley and was then summarized
(Table 2).
JBMR Plus (WOA)

Discussion
From its ﬁrst reporting in 1934(1) until evidence of genetic heterogeneity in 2013,(12) DSS seemed a distinctive Mendelian
OPT.(1,2,6–10,24) In 2010, we described in a girl with classic features
of DSS absence of OCs and unresorbed calciﬁed primary spongiosa emblematic of OPT.(4) In 2012, we reported that she and
a similarly affected girl manifested impaired osteoclastogenesis
and OC action and discovered they harbored biallelic SLC29A3
mutations.(5) In 2015, The International Skeletal Dysplasia Registry(25) regarded DSS as an OPT-like disorder.(2,6–10,24,26–30)
Although osteosclerosis and impaired bone modeling (ie,
“undertubulation”) characterize the OPTs including DSS, the platyspondyly and spontaneous resolution of the osteosclerosis of
DSS do not.(6,10) DSS features acquired platyspondyly and osteosclerosis (especially in the appendicular skeleton), but patchy
osteosclerosis later on, and osteopenia in adulthood.(6,10,11) Hence,
DSS has a particularly complex and enigmatic pathogenesis. The
changing skeletal phenotype can go undocumented or unappreciated and therefore undiagnosed. By 2022, among 23 individuals
with mutational analysis from 45 with the DSS phenotype,(6–
9,24,26–30)
six, four, two, and 11 had defects of SLC29A3, TNFRSF11A,
TCIRG1, or CSF1R, respectively.(5,11,20–23,31–36) The heterogeneity
among the clinical and radiological presentations, complications,
and prognoses for each etiology is as follows.

Our patients’ DSS
Patient 1, our oldest at 23 years old, provided almost a 20-year
follow-up, whereas patient 2 is the youngest reported with DSS
(Tables 1 and 2). Short stature was invariable(2,4–7,10,20,21,31–34)
whereas arm length was unaffected. Disproportionate dwarﬁsm
featuring a short trunk became a constant ﬁnding by adulthood
despite recurrent femoral fracturing. The body proportions of
patient 3 changed from age 10 to 17 years, highlighting her progressive trunk shortening. However, platyspondyly with a shortened trunk was not evident early on in our youngest patients
2 and 4. Patient 3’s fractures began relatively late; ie, in adolescence.
In DSS, discoloration and delayed eruption of teeth, dentition
embedded into the gum, frequent caries, and mandibular osteomyelitis have been reported.(7,9–11,16,20,24,26–28) Patients 1 and
2 had delayed shedding of deciduous teeth followed by delayed
eruption of permanent teeth, or were too young for teething,
respectively. Patient 3 suffered tooth decay. Patient 4 had discolored teeth. Only patient 3, homozygous for a TNFRSF11A mutation, had nystagmus due to optic atrophy from narrowed optic
canals related to the osteosclerosis of her cranial bones.

Fig. 4. Patient 4. Radiographic ﬁndings in early childhood. (A) At age
2 years, the skull has slightly increased vertical diameter. (B) There is
marked metadiaphyseal osteosclerosis and widening of the proximal
humeri, marked osteosclerosis and some widening of the ribs, and osteosclerosis of the spine, clavicles, and scapulae. (C.1,C.2) Between ages
2-1/3 and 4-1/3 years, osteosclerosis has decreased in the metaphyses
and carpals in the hands and wrists, and metadiaphyses in the radius
and ulna. Metadiaphyseal widening has increased. (D.1,D.2,E.1,E.2) Osteosclerosis has decreased in the pelvis and lateral spine and metadiaphyses
of the femurs and proximal tibias and ﬁbulas. Metadiaphyseal expansion
and cortical thinning are developing in the tubular bones.
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Herein, we found metaphyseal osteosclerosis in early childhood. However, patient 2 demonstrated it might not be present
neonatally, yet appear by age 2 months. For patient 1, followed
to age 22 years, metaphyseal osteosclerosis extended as she
grew, but mid-diaphyseal radiolucency persisted up to age
11 years. Then, patchy osteosclerosis with sparse radiolucency
involved the diaphyses. At older ages, radiolucent areas predominated, especially after physeal fusion and cessation of growth.
Axial osteosclerosis, including of the ribs, pelvis, and vertebrae in
patients 1, 3, and 4 was a more constant ﬁnding. However, in
patient 1 it was decreased during adulthood. In patient 3, osteosclerosis increased steadily with better demarcated focal osteosclerosis, especially mid-diaphyseal, and fracture-prone dense
bone within osteopenic long bones. Perhaps absence of apparent metaphyseal sclerosis together with unaffected hand and
forearm bones indicates DSS due to TNFRSF11A mutation.
Patient 4’s metaphyseal and marginal osteosclerosis faded by
age 4 years, leaving severely osteopenic long bones. Resolution
of osteosclerosis can occur in the carbonic anhydrase II deﬁciency form of OPT (OMIM, type 3),(3) perhaps because its unique
metabolic acidosis leaches mineral from bone.(37) Patient 4 manifested unexplained marked hypercalcemia once, but was without
a CA2 mutation or acidosis. Although no fractures had been
detected, perhaps his hypercalcemia reﬂected his immobility.
Hypercalcemia is not a feature of the OPTs unless following restoration of OC action by marrow cell transplantation.(38,39) In our initial patient harboring SLC29A3 mutations,(4,5) serum ionized
calcium was high-normal at approximately 1 year old, but
decreased after excessive dietary calcium was corrected.(4) In
DSS, low serum PTH levels can occur,(9,10) suggesting mineral
homeostasis is impacted. Hypocalcemia from decreased bone
resorption and diminished gastrointestinal absorption of calcium
underlies “osteopetrorickets” from TCIRG1 deactivation.(38,40)
Slow fracture healing can occur in DSS,(4) as in other OPTs.
Indeed, quiescent bone remodeling was suggested in our four
patients by low serum OCN levels and low-normal ALP activity.
Patients 1 and 2 had elevated urinary DPD, a marker of bone
resorption, whereas serum CTX levels were normal. However,
BTMs were inconsistent among our four patients, perhaps
reﬂecting their genetic heterogeneity for DSS as well as evolving
skeletal phenotype.

SLC29A3-associated DSS
The two unrelated girls we reported in 2012 with DSS were compound heterozygous (c.607T>C, p.Ser203Pro; c.1157G>A, p.Arg386Gln) and homozygous (c.1346C>G, p.Thr449Arg) for
SLC29A3 mutation.(5) The former had Turkish heritage.(4) Their
few OCs formed from peripheral blood weakly demineralized a
crystalline calcium-phosphate surface.(4,5) Low serum tartrateresistant acid phosphatase (TRAP) matched a paucity of OCs.(4)
Therefore, OC formation and function in DSS can become
impaired and increase bone mass, but then apparently recover
sufﬁciently to resorb calciﬁed primary spongiosa and osteosclerosis. Currently, however, OMIM(3) does not mention our
2010 report of OC-poor OPT in DSS(4) and considers the two
patients examples of “H syndrome” or “histiocytosislymphadenopathy plus syndrome” (602782), which features
biallelic SLC29A3 mutation causing short stature (but not fracturing), histiocytosis, and lymphadenopathy with or without cutaneous, cardiac, and/or endocrine features (insulin-dependent
diabetes mellitus, hypogonadism), joint contractures, and/or
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deafness. Now, six individuals have been reported to have DSS
from SLC29A3 mutation.(5,21,31,32)

TNFRSF11A-associated DSS
Beginning in 2008,(18) homozygous mutation of TNFRSF11A
encoding RANK was reported to cause “OC-poor” OPT. About
20 examples are published.(18,39–46) However, in 2018 Guo and
colleagues(20) speciﬁed that our patient 3 had DSS. Now, they
attribute the DSS phenotype to four individuals with biallelic
loss-of-function defects in TNFRSF11A.(11,20,33,34) Splice site mutations of TNFRSF11A, exempliﬁed by our patient 3, that truncate or
extend the encoded RANK protein can cause DSS(11,20) whereas
“DSS” from TNFRSF11A missense mutation p.R129C(34) featured
diffuse osteosclerosis and extramedullary hematopoiesis consistent with a severe OPT. TNFRSF11A mutations that alter
N-terminal folding of the encoded RANK and compromise its
interaction with RANKL(18) cause OPT, whereas some functional
RANK seems to cause DSS. Nevertheless, the skeletal phenotype
of the severe OPT, can also improve with aging.(11) The eldest
person (age 59 years) reported with biallelic TNFRSF11A mutations had severely osteopenic long bones.(11)

TCIRG1-associated DSS
In 2018, in two siblings, compound heterozygosity of TCIRG1
(c.117+4A>C with c.2380_2381delCT, p.A796fs*34) reportedly
caused metaphyseal sclerosis typical of DSS.(21) TCIRG1 encodes
a component of the vacuolar proton (H+) pump, and biallelic
mutations thereby cause “osteopetrorickets” from an abundance of nonfunctional OCs together with impaired gastrointestinal absorption of calcium due to hypochlorhydria.(38,40) The
OPT from biallelic TCIRG1 defects is “OC-rich” and treatable by
hematopoietic stem cell transplantation that generates functional OCs.(19,38,40,41) The TCIRG1 splice site mutation at the
beginning of this paragraph (c.117+4A>C), is homologous to
splice site mutation c.117+4A>T reported in 2000 to cause
OPT(47) in a Turkish patient. When this mutation accompanied p.A796fs*34 above, the phenotype was milder.

LRRK1-associated osteosclerotic metaphyseal dysplasia
The eight individuals reported to date with “osteosclerotic metaphyseal dysplasia” (OMIM % 615198)(3) harbored homozygous
defects of LRRK1.(13–17) Their clinical and radiographic features
of DSS resemble those attributable to SLC29A3 or TCIRG1 mutation, including fractures without severe extramedullary hematopoiesis or short stature.(13–17) Radiological features include
metaphyseal and vertebral sclerosis with mildly under-modeled
long bones that may evolve, including diminishing metaphyseal
sclerosis.(14) However, there is no prominent platyspondyly.

CSF1R-associated DSS-Pyle disease spectrum
The “DSS-Pyle disease spectrum” features generalized osteosclerosis and irregular dysplastic metaphyses associated with
neonatal and infant lethality from leukoencephalopathy, intracranial calciﬁcation, Dandy-Walker malformation, cystic dilation
of the posterior fossa and ventricles, and agenesis of the corpus
callosum.(48,49) In 2017, in ﬁrst-cousin carrier parents, heterozygous mutation (p.Y540*) of CSF1R was detected.(48) Biallelic
CSF1R mutations were identiﬁed by Guo and colleagues(22) and
Kındış and colleagues(35) in 2019 and 2021, respectively. The
2019 report(49) concerned a homozygous splice acceptor site
JBMR Plus (WOA)

mutation (c.1754 1G>C), published back-to-back by Guo and
colleagues.(22) However, these two reports describe an osteosclerotic phenotype atypical for DSS.(48,49) In fact, biallelic CSF1R
defects do not always have a bone phenotype; eg, the second
case, harboring p.H643Q, reported in 2019 by Oosterhof and
colleagues,(49) and two siblings with the p.T833M mutation.(50)
Monoallelic CSF1R mutation underlies hereditary diffuse leukoencephalopathy with spheroids (HDLS)—a rapidly progressive
lethal neurodegenerative disease of adults that features cerebral
white matter, behavioral, cognitive, and motor changes as well
as dementia.(51) However, no bone changes were reported in
2021 by Guo and Ikegawa from a relatively large experience.(52)
Typical HDLS has occurred with “sclerosing skeletal dysplasia”,
with undertubulation and ﬂaring of the metaphyses of most of
the tubular long bones and ﬁsh-shaped vertebrate.(36) An osteosclerotic adolescent boy with HDLS reported in 2020 by Breningstall and Asis(36) was heterozygous for CSF1R p.Q481*. His
radiographs, kindly provided to us by Dr. G.N. Breningstall
(unpublished), showed platyspondyly and osteopenic long
bones with Erlenmeyer ﬂask deformity and focal osteosclerosis.
His CSF1R defect was compound heterozygous in a patient with
“brain abnormalities, neurodegeneration, and dysosteosclerosis” (BANDDOS: OMIM # 618476).(22) The father, who was heterozygous, had mild cortical hyperostosis and normal cranial
tomography, yet short-term memory loss from age 70 years,
and parenchymal calciﬁcation were detected in the 76-year-old
paternal grandfather, who was also heterozygous.(22)
Our patient 4, lacking identiﬁcation of a causal gene, uniquely
suffered severe mental/motor retardation, infections, and one
episode of severe unexplained hypercalcemia. In DSS, infections
have been frequent without any detectable immune defect.(4,5)
Neurodevelopmental delay, macrocephaly, seizures, intracranial
calciﬁcation, and delayed myelination are features of the DSSPyle disease spectrum.(7,9,22,35) His cranial MRI showed a myelinization defect, but no leukoencephaly or ﬁndings of Pyle disease.
Microcephaly, not macrocephaly, was present.

DSS from SLC29A3 versus TNFRSF11A mutation
The DSS phenotype associated with SLC29A3 and TNFRSF11A
mutations features short stature. However, fracturing sometimes
with slow healing (eg, patient 1),(5) begins earlier and seems
more common with SLC29A3 mutations (eg, patients 1 and 2).
Metaphyseal sclerosis characteristic of DSS was not observed at
different ages in three of four patients harboring TNFRSF11A
mutations.(11,20,33,34) The exception differed from DSS because
diffuse diaphyseal sclerosis ended with a small area of osteopenia and continued with the osteosclerotic metaphyses.(33)
TNFRSF11A-associated DSS features particularly severe osteosclerosis of the axial skeleton together with optic atrophy, craniosynostosis, and extramedullary hematopoiesis.(34) Contrary to
DSS from defective SLC29A3 and TCIRG1, mild TNFRSF11A mutations likely leave hand bones unaltered (eg, patient 3), whereas
severely compromised RANK protein can cause marked osteosclerosis of the entire skeleton including hand bones.(33,34)

heterogeneity, including an X-linked recessive form,(24) seems
likely. In clinical practice, establishing the genetic basis for DSS
will help understand the complications, prognosis, and
treatment.
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